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Abstract
An efﬁcient and stability-indicating method has been developed and validated for the quantitative
determination of tetrahydrofuran (THF), a hydrolytic degradation impurity, in Busulfan injectable
pharmaceutical products by using gas chromatograph equipped with a liquid autosampler and a
ﬂame ionization detector. The chromatographic separation was performed on a fused silica capillary
(Stabilwax; 60 m length × 0.32 mm i.d., 0.5 µm ﬁlm thickness) column. Themethodologywas validat-
ed in accordance with regulatory guidelines. The proposed method was found to be speciﬁc, stable,
precise, linear, accurate, robust, and rugged in the concentration range from 4 to 1,080 ppm for THF.
The developedmethodwas successfully applied to determine the THF content in Busulfan injectable
pharmaceutical products.
Introduction
Busulfan is a white crystalline powder with a molecular formula of
CH3SO2O(CH2)4OSO2CH3 and amolecularweight of 246 (Figure 1).
Busulfan is a bifunctional alkylating antineoplastic agent. It belongs to
the class of alkyl sulfonates with the chemical name 1,4-butanediol di-
methanesulfonate. Busulfan is considered as the mainstay of the che-
motherapeutic treatment of chronic myeloid leukemia and similar
disorders (1, 2).
Initially, Busulfan was introduced as an oral drug. Later an intra-
venous busulfan injectable formulation was developed to overcome
the dosing-related issues. The injectable formulation of busulfan is
currently available in the market as BUSULFEX®, as a clear, colorless,
sterile solution in 10 mL single-use vials. Each vial contains 60 mg
(6 mg/mL) of busulfan as an active ingredient. Busulfan is dissolved
in N,N-dimethylacetamide, 33% (v/v) and polyethylene glycol 400,
67% (v/v). The solubility of busulfan in water is 0.1 g/L and the pH
of BUSULFEX diluted to ∼0.5 mg/mL in 0.9% sodium chloride
(USP) or 5% dextrose (USP) as recommended for infusion reﬂects
the physiological pH ranges (1, 2).
The degradation pathway of busulfan in aqueous solution has
been investigated (1, 3–6). Busulfan yields 4-hydroxybutyl methane-
sulfonate and methanesulfonic acid as degradation products. Further-
more, the unstable intermediate 4-hydroxybutyl methanesulfonate
undergoes cyclization to tetrahydrofuran (THF) and 1,4-butanediol.
The level of formation of THF depends on the rate of cyclization of
4-hydroxybutyl methanesulfonate.
Among the above-mentioned degradation products depicted in
Figure 2, THF is one of the toxic impurities listed under the residual
solvents class II. The permitted daily exposure of THF is 7.2 mg (not
more than 720 ppm) and the impurity level with respect to maximum
daily dose of Busulfan (224 mg) is 3.2%.
Hence, according to International Conference on Harmonization
(ICH) guidelines (7), it is obligatory to monitor the THF level in the
drug product Busulfan injection (8, 9).
Literature survey reveals that thus far (10–14), Hassan and Ehrs-
son reported a gas chromatographic method which includes an elec-
tron capture detector and a ﬂame ionization detector (FID) for the
identiﬁcation of THF in the hydrolysis degradation study for busulfan
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drug substance. However, there is a signiﬁcant need for a speciﬁc
methodology for the quantitative determination of THF in busulfan
injectable drug formulations.
This paper presents a simple and stability indicating GC-FID (gas
chromatograph equipped with ﬂame ionization detector, FID) method
for the quantitative determination of THF in Busulfan injectable phar-
maceutical products. The proposed method is sensitive at lower con-
centration (4 ppm) of THF. The speciﬁcity and stability of the method
was proved from the spiking and degradation study. The precision, lin-
earity and accuracy of the method was demonstrated for THF in the
concentration range from the limit of quantitation (∼25 ppm) level to
150% (∼1080 ppm) of nominal concentration (720 ppm).
Experimental
Chemicals and standards
THF standard (GC grade standard with purity 99.98% obtained from
Sigma-Aldrich), acetone (GC grade solvent with purity 99.8 obtained
from Merck), water (MilliQ), dimethylacetamide (GC grade solvent
with purity 99.5% obtained from Merck), 1,4-butanediol (GC
grade solvent with purity 99.8% obtained from Sigma-Aldrich) and
polyethylene glycol (PEG-400) (GC grade solvent obtained from
Merck) were used in the experiment.
Instrumentation and chromatographic conditions
A gas chromatograph equipped with a liquid auto sampler and an FID
(7890A, Agilent Technologies with EZ-Chrome software) was used to
perform the analysis. Samples were introduced in a split/splitless injec-
tion port and the detection was performed bymeans of FID. A capillary
(Stabilwax; 60 m length, 0.32 mm inner diameter and 0.5 µm ﬁlm
thickness) column (Restek) was used for separation. The column oven
temperature was programmed with an initial temperature of 50°C for
15 min and then increased to 230°C at the rate of 20°C/min, held at
230°C for 19 min and then increased to 240°C at the rate of 20°C/
min, held at 240°C for 26.5 min. The total run time was 70 min. The
injector and detector temperatures were kept at 270 and 275°C, respec-
tively. Nitrogen was used as a carrier gas. The gradient carrier gas ﬂow
rate was programmed with an initial ﬂow rate of 1 mL/min, up to
20 min, and increased to 2 mL/min, up to 70 min. Nitrogen gas was
used as a makeup gas for FID and the ﬂow rate was 20 mL/min, where-
as for hydrogen gas and zero air ﬂow rate was 30 and 300 mL/min, re-
spectively. The split ratio was set at 50:1 and the purge ﬂow rate was
15 mL/min. The sample solutions were injected by a liquid autosampler
of GC with an injection volume of 1 µL.
Standard and test sample solution preparation
The standard solution of THF was prepared in acetone to obtain a
ﬁnal concentration of ∼0.144 mg/mL, and the test sample solution
was prepared in acetone to obtain a ﬁnal concentration of 200 mg/mL.
Validation of the method
Validation of the method was performed as per the ICH (Q2R1),
USP<1225> validation guidelines and also other guidelines with respect
to global regulatory requirement (7–9, 15–20). As part of method val-
idation, parameters such as speciﬁcity, forced degradation, precision,
ruggedness, linearity, accuracy, lowest detection limit (LDL) and lowest
quantitation limit (LQL), robustness, solution stability, system suitabil-
ity, and range of the test method were evaluated.
Speciﬁcity and forced degradation
Speciﬁcity of the method was evaluated by analyzing blank (acetone),
standard solution (THF), test sample solution, placebo solution (sam-
ple without drug), and test sample solution spiked with standard.
Forced degradation was performed by subjecting the sample to hy-
drolytic (the sample was treated with water at 50°C for 1 h), thermal
(the sample was kept in hot air oven at 80°C for 4 h) and photolytic
(the sample was exposed to 1.2 million Lux hours of cool ﬂuorescent
light and an integrated near-UV energy exposure of 200 W h/m2 si-
multaneously in a photostability chamber maintained at 25°C) degra-
dation under stressed conditions.
Precision (repeatability and reproducibility)
System precision (repeatability) was evaluated by injecting six replicate
injections of THF standard solution. For method precision (reproduc-
ibility), six sample solutions (n = 6) were prepared and analyzed. The
relative standard deviation (RSD) for area response and retention time
of standard in system precision, and concentration of THF in sample
were calculated.
Ruggedness
Ruggedness of the method was evaluated by performing the sample
analysis using different instrument, column, by different analyst on
different day. The cumulative RSDwas calculated for 12 sample deter-
minations (n = 12) obtained from intra- and inter-precision.
Linearity
From a stock standard solution of THF, different concentrations of
standard solution ranging from the lowest level (3.999 ppm) to
∼150% level (1,079.784 ppm) of the nominal standard concentration
(720 ppm) were prepared. The peak area responses were plotted
against the respective concentrations and the obtained data were sub-
jected to linear regression analysis.
Figure 2. Hydrolytic degradation pathway of Busulfan.
Figure 1. Structure of Busulfan.
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Lowest detection limit and lowest quantitation limit
The lowest detection limit and the lowest quantitation limit were de-
rived from the linearity slope and residual standard deviation. The de-
rived LDL and LQL for THF were 8 and 25 ppm, respectively. The
solutions of appropriate concentration were prepared and injected.
Accuracy (recovery) and range
Accuracy test was performed by analyzing the samples spiked with a
known amount of THF standard at LQL, 50, 100, 120, and 150% lev-
els. At LOQ and 150% level, six samples were prepared and triplicate
samples were prepared for other levels. The% recovery was calculated
from the amount of standard added and the amount of standard re-
covered.
The range of the test method was derived based on the precision,
linearity and recovery obtained from the accuracy study in the pres-
ence of test sample matrix ranging from lower to upper limits.
The linearity of the test method across the rangewas drawn from the
mean values of “amount added” and “amount recovered” at each level.
Robustness
For evaluation of robustness, standard solution of THF, sample spiked
with THF standard at 100% level, was prepared and analyzed under
different experimental conditions by varying different chromato-
graphic parameters; initial carrier gas ﬂow rate (0.8, 1 and 1.2 mL/
min), initial column oven temperature (45, 50 and 55°C/min), injector
temperature (265, 270 and 275°C) and detector temperature (270,
275 and 280°C). The RSD for area response, symmetry factor and re-
covery were evaluated under each varied method condition.
Stability of analytical solutions
For evaluation of analytical solution stability, THF standard solution
and test sample solution were prepared and analyzed for different time
intervals at ambient temperature (25 ± 2°C). The % difference for peak
area responses between initial and each time interval was evaluated.
System suitability
The system suitability was evaluated for THF standard solution in all
of the parameters of the validation study. RSD for peak area responses
and USP symmetry factor were calculated.
Results
Method validation
Speciﬁcity and forced degradation
The obtained chromatograms for standard solution, sample solution,
sample solution spiked with standard and degraded samples showed
no interference with THF peak, proving that the method is speciﬁc
(Figures 3 and 4).
The sample found degraded under thermal-stressed (∼30% degra-
dation; THF% level observed is 0.74%) and Neutral-stressed (∼27%
degradation; THF% level observed is 0.67%) conditions. However,
no unknown impurities were found that could have interfered with
the THF peak, proving that the method is stability indicating (Fig-
ures 5–7).
Precision (repeatability and reproducibility)
System precision (repeatability) was determined from the area re-
sponse and retention time of the THF peak obtained from six repeat-
able standard determinations. The %RSD was 0.5 and 1.8 for the
retention time and peak area response, respectively, which indicates
the repeatability of the method.
Method precision (reproducibility) was conﬁrmed from the six re-
producible results of quantiﬁcation acquired from the single lot of homo-
geneous test sample. The % RSD for the quantiﬁed results of THF from
samples found 1.1%, which indicates the reproducibility of method.
Ruggedness
The%RSD for the quantiﬁed results of THF obtained from 6 determi-
nations (inter-precision) was 1.5 and the cumulative %RSD for 12 de-
terminations (obtained from intra- and inter-precision) was found 1.2,
indicating that the method is rugged.
Figure 3. Chromatogram of THF standard solution.
Figure 4. Chromatogram of sample spiked with THF standard.
Figure 5. Chromatogram of neutral stressed sample.
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Linearity
A linear correlation and regression was found between the peak area
responses and concentrations of THF in the speciﬁed range (lowest
quantitation limit to 150% of nominal concentration). The data pre-
sented in Table I indicate the linearity of method (Figure 8).
Lowest detection limit and lowest quantitation limit
The LDL and the LQL were evaluated for the derived LDL and LQL
for THF (8 and 25 ppm). The %RSD for the THF peak area response
at LQL concentration obtained for six determinations was 2.0%, and
a distinct visible peak was observed at LDL concentration, proving
that the method is sensitive (Figure 9).
Accuracy (recovery) and range
Accuracy test was performed by analyzing the spiked samples at LQL,
50, 100, 120 and 150% level. The overall mean % recovery was
98.7% (RSD = 0.9%). The results tabulated in Table II indicate the re-
covery efﬁciency of the method.
The range of THF concentration recovery from sample matrix was
found linear, accurate and precise at lower and higher levels. A linear
graph was drawn between the mean values of “amount added” and
“amount recovered” from the LQL to 150% level (Figure 10).
Robustness
The robustness of the test method was evaluated for minor but delib-
erate variations in the method conditions. The variation factors such
as initial carrier gas ﬂow rate (0.8, 1 and 1.2 mL/min), initial column
oven temperature (45, 50 and 55°C/min), injector temperature (265,
270 and 275°C) and detector temperature (270, 275 and 280°C)
were considered. The effect of variations in method conditions was
evaluated for area response, symmetry factor and recovery. The data
represented in Table III indicates that the methodology was not affect-
ed from the deviations in chromatographic conditions and thus the re-
liability of the method.
Stability of standard and test sample solutions
The standard and test sample solution stability was evaluated for dif-
ferent time intervals at ambient temperature (25 ± 2°C). The %
Figure 6. Chromatogram of thermal stressed sample.
Figure 7. Chromatogram of photolytic stressed sample.
Table I. Linearity Curve for THF
% Level Concentration (ppm) Peak area response
0.5 3.9992 958
1.25 8.9982 2,863
2.5 17.9964 5,032
5 35.9928 11,342
10 71.9856 22,467
25 179.964 52,621
50 359.928 109,853
80 575.8848 174,628
100 719.856 216,952
120 863.8272 250,439
150 1,079.784 303,517
Correlation coefﬁcient (r) 0.999
Regression coefﬁcient (R2) 0.998
Slope 287.98439
y-intercept 2,026.08214
% y-intercept 0.93
Figure 8. Linearity curve for THF peak area response.
Figure 9. Chromatogram of limit of quantitation.
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difference for peak area responses between initial and each time inter-
val was calculated.
The % difference in the peak area responses from initial to 48 h
obtained for standard and test solution was −0.8 and 1.2%, respec-
tively, which indicates that the analytical solutions were stable at
least for 48 h.
System suitability
For all parameters of validation, the speciﬁed system suitability param-
eters: RSD for peak area response and USP symmetry factor were eval-
uated for THF standard solution and found% RSD <10.0% and USP
symmetry factor <2.0, proving that the suitability of analytical system.
Discussion
Method development
Tetrahydrofuran impurity by nature is a solvent and estimation by
HPLC will be incompatible and inaccurate. Thus, the GC-FID meth-
odology is an appropriate technique. As the busulfan injectable prod-
uct formulation contains 67% of PEG-400, the separation of analyte
peak from the sample matrix is a typical task. The head space GC
method was tried to avoid the sample matrix. However, the headspace
method was found to be inappropriate due to the degradation of sam-
ple during heating in the head space oven. Hence, the GCmethod with
liquid injection sampler has been preferred.
To develop a stable GC-FIDmethod for the estimation of THF, dif-
ferent chromatographic factors were evaluated. These factors include
the selection of a suitable organic solvent for standard and sample
preparation (dimethylsulfoxide, dimethylformamide, dimethylaceta-
mide, methanol, ethanol, acetone), columns with different stationary
phase and different dimensions (nonpolar columns like DB-5, HP-1;
mid-polar columns like DB-624 and polar columns like HP-WAX,
DB-FFAP, Stabilwax) and GC chromatographic (injector, detector
and oven temperature program) conditions.
Table II. Accuracy and Range
Accuracy level Sample Amount added (ppm) Amount recovered (ppm) % Recovery Mean % recovery % RSD
LOQ 1 24.641 24.189 98.2 98.0 1.1
2 24.641 23.739 96.3
3 24.641 24.488 99.4
4 24.641 24.009 97.4
5 24.641 24.395 99.0
6 24.641 24.015 97.5
50% 1 362.365 359.029 99.1 98.9 0.6
2 362.365 355.997 98.2
3 362.365 359.956 99.3
100% 1 724.73 717.746 99.0 99.3 0.2
2 724.73 721.038 99.5
3 724.73 719.398 99.3
120% 1 869.676 854.556 98.3 99.4 1.1
2 869.676 872.880 100.4
3 869.676 865.866 99.6
150% 1 1,087.095 1,065.026 98.0 98.6 0.7
2 1,087.095 1,062.713 97.8
3 1,087.095 1,079.688 99.3
4 1,087.095 1,074.613 98.9
5 1,087.095 1,071.520 98.6
6 1,087.095 1,080.357 99.4
Overall mean % recovery 98.7
Overall mean % RSD 0.9
Figure 10. Linearity curve for THF recovery.
Table III. Robustness
Chromatographic
condition
USP
symmetry
factor
%RSD for
THF peak
area response
% Recovery
of THF from
spiked sample
Original conditions 1.1 1.8 99.3
Increase in ﬂow 1.0 1.4 99.6
Decrease in ﬂow 1.1 1.1 99.4
Increase in column oven
temperature
1.6 1.2 99.5
Decrease in column oven
temperature
1.2 1.1 99.3
Increase in injector
temperature
1.4 1.1 99.1
Decrease in injector
temperature
1.3 1.2 99.3
Increase in detector
temperature
1.4 1.1 99.4
Decrease in detector
temperature
1.2 1.8 99.2
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The ﬁnal methodology was optimized based on the solubility of
standard and sample in acetone, separation of analyte from the sample
matrix and good recovery using the Stabilwax column under ideal GC
chromatographic conditions.
Conclusion
A gas chromatography with FID (GC-FID) method for the determina-
tion of THF, a hydrolytic degradation impurity in busulfan injectable
pharmaceutical product, was developed and validated as per analyti-
cal quality-by-design approach. The method was found to be speciﬁc,
sensitive, linear, accurate and robust. The developedmethodology was
successfully applied to determine the degradation impurity, THF, in
test samples of busulfan injectable product. Hence, this methodology
can be adopted by quality control laboratories in the regular and
stability analysis for the determination and control of THF impurity
in busulfan injectable formulation products.
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